Gainers
- Plus Therapeutics PSTV shares rose 20.3% to $1.48 during Tuesday's after-market session. Today's trading volume for this security ended up closing at 1.0 million shares, which is 236.3 percent of its average volume over the last 100 days. The market value of their outstanding shares is at $4.2 million. The company's, Q3 earnings came out today.
- NewAmsterdam Pharma NAMS shares increased by 11.11% to $10.0. The company's market cap stands at $823.2 million.
- China SXT Pharmaceuticals SXTC shares increased by 10.23% to $2.37. The company's market cap stands at $1.3 million.
- DarioHealth DRIO stock moved upwards by 7.81% to $1.38. The market value of their outstanding shares is at $37.5 million.
- Pluri PLUR shares moved upwards by 7.75% to $0.55. The company's market cap stands at $22.5 million.
- Oncology Institute TOI shares moved upwards by 7.32% to $2.05. The company's market cap stands at $149.5 million.
Losers
- Alaunos Therapeutics TCRT shares declined by 7.9% to $0.07 during Tuesday's after-market session. Alaunos Therapeutics's trading volume hit 388.2K shares by close, accounting for 14.0% of its average volume over the last 100 days. The market value of their outstanding shares is at $17.7 million.
- Blue Water Biotech BWV shares declined by 7.44% to $0.36. The company's market cap stands at $6.4 million.
- Vaccitech VACC shares declined by 6.32% to $3.93. The company's market cap stands at $151.6 million.
- Onconova Therapeutics ONTX stock decreased by 5.99% to $0.6. The market value of their outstanding shares is at $12.6 million.
- Applied Molecular AMTI shares decreased by 5.6% to $0.14. Today's trading volume for this security ended up closing at 115.0K shares, which is 10.3 percent of its average volume over the last 100 days. The market value of their outstanding shares is at $5.3 million.
- NeuroBo Pharmaceuticals NRBO stock declined by 5.55% to $0.41. The market value of their outstanding shares is at $15.7 million. See Also: www.benzinga.com/money/best-healthcare-stocks/
This article was generated by Benzinga's automated content engine and reviewed by an editor.
Market News and Data brought to you by Benzinga APIs
© 2024 Benzinga.com. Benzinga does not provide investment advice. All rights reserved.
Benzinga simplifies the market for smarter investing
Trade confidently with insights and alerts from analyst ratings, free reports and breaking news that affects the stocks you care about.
Join Now: Free!
Already a member?Sign in